These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 25201135

  • 1. Mid-regional pro-adrenomedullin: an indicator of the failing Fontan circuit in patients with univentricular hearts?
    Kaiser R, Abdul-Khaliq H, Wilkens H, Herrmann E, Raedle-Hurst TM.
    Eur J Heart Fail; 2014 Oct; 16(10):1082-8. PubMed ID: 25201135
    [Abstract] [Full Text] [Related]

  • 2. Mid-region pro-adrenomedullin adds predictive value to clinical predictors and Framingham risk score for long-term mortality in stable outpatients with heart failure.
    Xue Y, Taub P, Iqbal N, Fard A, Clopton P, Maisel A.
    Eur J Heart Fail; 2013 Dec; 15(12):1343-9. PubMed ID: 23887059
    [Abstract] [Full Text] [Related]

  • 3. Mid-regional pro-adrenomedullin in patients with acute dyspnea: Data from the Akershus Cardiac Examination (ACE) 2 Study.
    Pervez MO, Lyngbakken MN, Myhre PL, Brynildsen J, Langsjøen EC, Høiseth AD, Christensen G, Omland T, Røsjø H.
    Clin Biochem; 2017 May; 50(7-8):394-400. PubMed ID: 28065681
    [Abstract] [Full Text] [Related]

  • 4. Comparison of long-term prognostic value of N-terminal-proBNP and midregional-pro-adrenomedullin in patients with acute myocardial infarction.
    Walter T, Brueckmann M, Lang S, Sauer T, Fiedler E, Papassotiriou J, Behnes M, Elmas E, Borggrefe M, Bertsch T.
    Clin Lab; 2010 May; 56(7-8):303-9. PubMed ID: 20857894
    [Abstract] [Full Text] [Related]

  • 5. Diagnostic performance of mid-regional pro-adrenomedullin as an analyte for the exclusion of left ventricular dysfunction.
    Elmas E, Lang S, Dempfle CE, Kälsch T, Papassotiriou J, Morgenthaler NG, Borggrefe M, Brueckmann M.
    Int J Cardiol; 2008 Aug 01; 128(1):107-11. PubMed ID: 17698224
    [Abstract] [Full Text] [Related]

  • 6. Midregional proadrenomedullin (MR-proADM) in the risk stratification of patients with acute pulmonary embolism.
    Pedowska-Włoszek J, Kostrubiec M, Kurnicka K, Ciurzynski M, Palczewski P, Pruszczyk P.
    Thromb Res; 2013 Nov 01; 132(5):506-10. PubMed ID: 24060192
    [Abstract] [Full Text] [Related]

  • 7. Mid-regional pro-adrenomedullin in the early evaluation of acute chest pain patients.
    Haaf P, Twerenbold R, Reichlin T, Faoro J, Reiter M, Meune C, Steuer S, Bassetti S, Ziller R, Balmelli C, Campodarve I, Zellweger C, Kilchenmann A, Irfan A, Papassotiriou J, Drexler B, Mueller C.
    Int J Cardiol; 2013 Sep 30; 168(2):1048-55. PubMed ID: 23199555
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of mid-regional pro-atrial natriuretic peptide, procalcitonin, and mid-regional pro-adrenomedullin for the diagnosis and risk stratification of dyspneic ED patients.
    Cinar O, Cevik E, Acar A, Kaya C, Ardic S, Comert B, Yokusoglu M, Bilgi C, Meisner M, Madsen T.
    Am J Emerg Med; 2012 Nov 30; 30(9):1915-20. PubMed ID: 22742951
    [Abstract] [Full Text] [Related]

  • 9. Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea.
    Shah RV, Truong QA, Gaggin HK, Pfannkuche J, Hartmann O, Januzzi JL.
    Eur Heart J; 2012 Sep 30; 33(17):2197-205. PubMed ID: 22645194
    [Abstract] [Full Text] [Related]

  • 10. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial.
    Maisel A, Mueller C, Nowak R, Peacock WF, Landsberg JW, Ponikowski P, Mockel M, Hogan C, Wu AH, Richards M, Clopton P, Filippatos GS, Di Somma S, Anand I, Ng L, Daniels LB, Neath SX, Christenson R, Potocki M, McCord J, Terracciano G, Kremastinos D, Hartmann O, von Haehling S, Bergmann A, Morgenthaler NG, Anker SD.
    J Am Coll Cardiol; 2010 May 11; 55(19):2062-76. PubMed ID: 20447528
    [Abstract] [Full Text] [Related]

  • 11. Diagnostic performance and reference values of novel biomarkers of paediatric heart failure.
    Hauser JA, Demyanets S, Rusai K, Goritschan C, Weber M, Panesar D, Rindler L, Taylor AM, Marculescu R, Burch M, Wojta J, Michel-Behnke I.
    Heart; 2016 Oct 15; 102(20):1633-9. PubMed ID: 27220692
    [Abstract] [Full Text] [Related]

  • 12. Predictive value of midregional pro-adrenomedullin compared to natriuretic peptides for incident cardiovascular disease and heart failure in the population-based FINRISK 1997 cohort.
    Funke-Kaiser A, Havulinna AS, Zeller T, Appelbaum S, Jousilahti P, Vartiainen E, Blankenberg S, Sydow K, Salomaa V.
    Ann Med; 2014 May 15; 46(3):155-62. PubMed ID: 24506434
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Thirty and ninety days mortality predictive value of admission and in-hospital procalcitonin and mid-regional pro-adrenomedullin testing in patients with dyspnea. Results from the VERyfing DYspnea trial.
    Travaglino F, Russo V, De Berardinis B, Numeroso F, Catania P, Cervellin G, Nigra SG, Geraci F, Bressan MA, Guerrini S, Cavazza M, Folli C, Monzani V, Battista S, Mengozzi G, Noto P, Carpinteri G, Semplicini A, Stella F, Ingrassia S, Moscatelli P, Giuntini P, Salerno G, Cardelli P, Di Somma S.
    Am J Emerg Med; 2014 Apr 15; 32(4):334-41. PubMed ID: 24559907
    [Abstract] [Full Text] [Related]

  • 15. Midregional pro-adrenomedullin as a predictor for therapeutic response to midodrine hydrochloride in children with postural orthostatic tachycardia syndrome.
    Zhang F, Li X, Ochs T, Chen L, Liao Y, Tang C, Jin H, Du J.
    J Am Coll Cardiol; 2012 Jul 24; 60(4):315-20. PubMed ID: 22813609
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study.
    Khan SQ, O'Brien RJ, Struck J, Quinn P, Morgenthaler N, Squire I, Davies J, Bergmann A, Ng LL.
    J Am Coll Cardiol; 2007 Apr 10; 49(14):1525-32. PubMed ID: 17418290
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Pro-A-type natriuretic peptide, proadrenomedullin, and N-terminal pro-B-type natriuretic peptide used in a multimarker strategy in primary health care in risk assessment of patients with symptoms of heart failure.
    Alehagen U, Dahlström U, Rehfeld JF, Goetze JP.
    J Card Fail; 2013 Jan 10; 19(1):31-9. PubMed ID: 23273592
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.